Minerva Neurosciences (NERV) FCF Margin (2020)
Minerva Neurosciences (NERV) reported FCF Margin of 18.43% for Q2 2020.
Minerva Neurosciences (NERV) FCF Margin (2020) Analysis & Trends
Minerva Neurosciences has reported FCF Margin for 1 years, with the latest figure at 18.43% in Q2 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -3.98% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 43.35% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Minerva Neurosciences | 197.55 Mn | 197.55 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2020 | -18.43% |